Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.41 |
| ▸ | BACE1 | P56817 | 6/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.36 |
| ▸ | CTSD | P07339 | 5/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 2/20 | 0.33 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.33 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493513 | 0.88 | CTSA (0.46) | MGLLPLA2G7CTSAMLLT3MLLT1 | |
| SCHEMBL2493286 | 0.87 | MGLL (0.34) | MGLLPLA2G7CTSAMLLT3MLLT1 | |
| SCHEMBL2501417 | 0.85 | BACE1 (0.37) | BACE1BACE2CTSDMLLT3MLLT1 | |
| SCHEMBL2503497 | 0.85 | MGLL (0.49) | MGLLPLA2G7CTSA | |
| SCHEMBL2493492 | 0.84 | CTSA (0.36) | BACE1BACE2CTSDCTSA | |
| SCHEMBL2499279 | 0.84 | CTSA (0.47) | MGLLPLA2G7CTSAMLLT3MLLT1 | |
| SCHEMBL2502844 | 0.84 | HSD17B14 (0.38) | BACE1BACE2CTSDMLLT3MLLT1 | |
| SCHEMBL2502465 | 0.84 | MGLL (0.45) | MGLLPLA2G7CTSAMLLT3MLLT1 | |
| SCHEMBL2496589 | 0.84 | CTSA (0.49) | MGLLCTSA | |
| SCHEMBL2501045 | 0.83 | GABRA1 (0.41) | MGLLPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | claimed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | claimed |
| US-8030339-B2 | Imidazole derivatives for the treatment of anxiety and related diseases | NEUROSEARCH A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | US | disclosed |
| EP-1937649-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042546-A1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES | NEUROSEARCH A/S (DK) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233929-A1 | Imidazole Derivatives for the Treatment of Anxiety and Related Diseases | GABBR1, GABRB2, GABRB3 | MGLL 4127/4885BACE1 1809/4885BACE2 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.